{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:28:38Z","timestamp":1788560918478,"version":"build-2803163510"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.1001\/jamaneurol.2022.0983","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T11:00:54Z","timestamp":1652094054000},"page":"565","source":"Crossref","is-referenced-by-count":47,"title":["Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome"],"prefix":"10.1001","volume":"79","author":[{"given":"Michael S.","family":"Rafii","sequence":"first","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sol","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Mobley","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Delpretti","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Skotko","sequence":"additional","affiliation":[{"name":"Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Burke","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna H.","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Pulsifer","sequence":"additional","affiliation":[{"name":"Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Evans","sequence":"additional","affiliation":[{"name":"Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Carol","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Beth","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fournier","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A.","family":"Gray","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Melo","family":"dos Santos","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Hliva","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Vukicevic","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kosco-Vilbois","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Streffer","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"AC Immune SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard H.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of California, San Diego, San Diego"},{"name":"Alzheimer\u2019s Disease Cooperative Study, University of California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi220019r1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","article-title":"Down syndrome.","volume":"6","author":"Antonarakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"noi220019r2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","article-title":"Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.","volume":"3","author":"Lemere","year":"1996","journal-title":"Neurobiol Dis"},{"issue":"3","key":"noi220019r3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2990.1984.tb00351.x","article-title":"Alzheimer\u2019s presenile dementia, senile dementia of Alzheimer type and Down\u2019s syndrome in middle age form an age related continuum of pathological changes.","volume":"10","author":"Mann","year":"1984","journal-title":"Neuropathol Appl Neurobiol"},{"key":"noi220019r4","doi-asserted-by":"publisher","author":"Mann","year":"1986","DOI":"10.1111\/j.1365-2990.1986.tb00053.x"},{"issue":"5","key":"noi220019r5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with Down syndrome.","volume":"12","author":"Annus","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"9","key":"noi220019r6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/jir.v61.9","article-title":"A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome.","volume":"61","author":"McCarron","year":"2017","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"noi220019r7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2018.3616","article-title":"Association of dementia with mortality among adults with Down syndrome older than 35 years.","volume":"76","author":"Hithersay","year":"2019","journal-title":"JAMA Neurol"},{"issue":"2","key":"noi220019r8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3233\/JAD-160836","article-title":"Down syndrome, partial trisomy 21, and absence of Alzheimer\u2019s disease: the role of APP.","volume":"56","author":"Doran","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"7409","key":"noi220019r9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline.","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"issue":"3","key":"noi220019r10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","article-title":"Dementia in Down syndrome: unique insights for Alzheimer disease research.","volume":"15","author":"Lott","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"noi220019r11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fnbeh.2015.00239","article-title":"The Down Syndrome Biomarker Initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer\u2019s disease biomarkers in Down syndrome.","volume":"9","author":"Rafii","year":"2015","journal-title":"Front Behav Neurosci"},{"issue":"2","key":"noi220019r12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JAD-170390","article-title":"PET imaging of tau pathology and relationship to amyloid, longitudinal MRI, and cognitive change in Down syndrome: results from the Down Syndrome Biomarker Initiative (DSBI).","volume":"60","author":"Rafii","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"10242","key":"noi220019r13","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","article-title":"Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study.","volume":"395","author":"Fortea","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"noi220019r14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.neurobiolaging.2004.08.005","article-title":"Alzheimer disease and Down syndrome: factors in pathogenesis.","volume":"26","author":"Lott","year":"2005","journal-title":"Neurobiol Aging"},{"issue":"4","key":"noi220019r15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/gim.2016.127","article-title":"Estimation of the number of people with Down syndrome in the United States.","volume":"19","author":"de Graaf","year":"2017","journal-title":"Genet Med"},{"issue":"3","key":"noi220019r16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41431-020-00748-y","article-title":"Estimation of the number of people with Down syndrome in Europe.","volume":"29","author":"de Graaf","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"23","key":"noi220019r17","doi-asserted-by":"publisher","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice.","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"noi220019r18","doi-asserted-by":"publisher","first-page":"13966","DOI":"10.1074\/jbc.M110.186338","article-title":"Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases.","volume":"286","author":"Hickman","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"noi220019r19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood-2012-02-413831","article-title":"TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell\u2013independent isotype switch in mice.","volume":"121","author":"Pihlgren","year":"2013","journal-title":"Blood"},{"issue":"1","key":"noi220019r20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nm0196-93","article-title":"Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down\u2019s syndrome.","volume":"2","author":"Teller","year":"1996","journal-title":"Nat Med"},{"issue":"3","key":"noi220019r21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152471","article-title":"An anti\u2013\u00df-amyloid vaccine for treating cognitive deficits in a mouse model of Down syndrome.","volume":"11","author":"Belichenko","year":"2016","journal-title":"PLoS One"},{"key":"noi220019r23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"noi220019r28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"noi220019r29","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01813-w"},{"issue":"1","key":"noi220019r31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/WAD.0b013e3181aba63a","article-title":"Increased soluble APPalpha, Abeta 1-42, and anti\u2013Abeta 1-42 antibodies in plasma from Down syndrome patients.","volume":"24","author":"Conti","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"noi220019r32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.trci.2018.10.006","article-title":"Alzheimer\u2019s disease in Down syndrome: an overlooked population for prevention trials.","volume":"4","author":"Strydom","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"noi220019r33","doi-asserted-by":"publisher","DOI":"10.1076\/jcen.20.3.310.823"},{"key":"noi220019r22"},{"key":"noi220019r24"},{"key":"noi220019r25"},{"key":"noi220019r26"},{"key":"noi220019r27"},{"key":"noi220019r30","unstructured":"Posner K, Brent D, Lucas C, et al. Columbia\u2013Suicide Severity Rating Scale. Version 6\/23\/10. Research Foundation for Mental Hygiene; 2010. Accessed June 1, 2015. https:\/\/cssrs.columbia.edu\/wp-content\/uploads\/C-SSRS_Pediatric-SLC_11.14.16.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2792226\/jamaneurology_rafii_2022_oi_220019_1653667065.54757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T11:13:25Z","timestamp":1655118805000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2792226"}},"subtitle":["A Phase 1b Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2022.0983","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}